Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare the effectiveness of receiving a
combination of ondansetron and aprepitant to receiving ondansetron alone in helping to
prevent nausea and/or vomiting in patients with Acute myeloid leukemia (AML) or high-risk
(HR) Myelodysplastic syndromes (MDS) who are receiving cytarabine. The safety of this drug
combination will also be studied.